Financial Results Approval

The Board of Directors approved the Unaudited Financial Results for the half year and quarter ended September 30, 2026, along with the Limited Review Report issued by the statutory auditors. The results were submitted to BSE Limited within 30 minutes after the conclusion of the Board meeting.

Key Financial Figures (₹ in Lakhs)

Quarter Ended September 30, 2026:

  • Revenue from operations: ₹0.04
  • Total income: ₹0.04
  • Employee benefits expenses: ₹18.82
  • Other expenditure: ₹2.40
  • Total expenses: ₹21.22
  • Loss before tax: ₹(21.18)
  • Net loss for the period: ₹(21.18)
  • Basic & diluted EPS: ₹(0.66)

Comparative Performance:

  • Q2 September 2025: Revenue ₹32.02 lakh, Net profit ₹0.33 lakh
  • Q1 June 2026: Revenue ₹15.20 lakh, Net loss ₹(12.49) lakh
  • Half Year September 2026: Revenue ₹15.24 lakh, Net loss ₹(33.67) lakh
  • Half Year September 2025: Revenue ₹65.30 lakh, Net loss ₹(1.37) lakh
  • FY2026 Audited: Revenue ₹133.57 lakh, Net loss ₹(277.69) lakh

Balance Sheet Position (as at September 30, 2026)

  • Total assets: ₹572.88 lakh
  • Non-current assets: ₹141.11 lakh (including property, plant & equipment ₹1.77 lakh, deferred tax assets ₹139.34 lakh)
  • Current assets: ₹431.77 lakh (including cash & cash equivalents ₹0.37 lakh, trade receivables ₹34.17 lakh, other financial assets ₹394.53 lakh)
  • Total equity: ₹378.67 lakh (share capital ₹401.32 lakh, other equity ₹(22.65) lakh)
  • Non-current liabilities (borrowings): ₹77.71 lakh
  • Current liabilities: ₹116.50 lakh (trade payables ₹81.59 lakh, other current liabilities ₹30.08 lakh, provisions ₹4.83 lakh)

Management Appointments

The Board approved the appointment of:

1. Mr. Firoze Kapadia as Chief Financial Officer (CFO) and Key Managerial Personnel with effect from November 02, 2026. Mr. Kapadia is engaged in agro commodities business operating in West Africa with strong background in agribusiness, strategic planning, and operational management. He is currently a director of the company.

2. Mr. Mehul Parekh as Chief Executive Officer (CEO) and Key Managerial Personnel with effect from November 02, 2026. Mr. Parekh is a pharmaceutical industry professional with over 40 years of experience, having served as Managing Director of a pharmaceutical company engaged in manufacture and export of Active Pharmaceutical Ingredients (APIs). He is currently a director of the company.

Annual General Meeting

The Board approved convening the Annual General Meeting on Tuesday, December 22, 2026 to transact ordinary and special businesses. The Notice of AGM together with the Annual Report for FY2026 will be circulated to members in due course. The company will separately intimate the cut-off date for determining eligibility for remote e-voting.

Meeting Details

The Board meeting commenced at 5:30 PM and concluded at 6:15 PM on November 02, 2026.

Additional Notes

  • The company operates in a single segment
  • Trade payables outstanding as on September 30, 2026 are not registered under MSME
  • Balances in various accounts are subject to confirmation/reconciliation
  • Previous period figures have been regrouped/rearranged where necessary